LAMA2-related dystrophy natural history study in children
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This study follows children with LAMA2-related muscular dystrophy to learn how the condition changes over time. It does not test a new treatment, but helps researchers understand the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be diagnosed with LAMA2-related muscular dystrophy, confirmed by genetic testing or a muscle biopsy.
- Your child must not have any other confirmed genetic brain or nerve disease.
- Your child must be willing to keep their current exercise and physical therapy routine during the study.
- Your child must be able to follow all study procedures and visit schedules.
- Your child must be covered by French social security or a health plan accepted in France.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.
This study follows people with LAMA2-related muscular dystrophy (a genetic muscle-weakening condition) to learn how it changes over time and find better ways to measure it. By participating, you help researchers identify new disease markers that could improve future treatments.
This study follows young children with LAMA2-related congenital muscular dystrophy to learn more about the disease. It does not test a new treatment, so it may help families understand the condition better and prepare for future trials.
This study follows people with LAMA2-related muscular dystrophy or SELENON-related myopathy over 5 years to understand how the condition changes over time. It may help you by tracking your disease progression and contributing to future research.
This study looks at a new protein that might help people with LAMA2-related muscular dystrophy. It uses stored samples to see if the protein could be a useful addition to future treatments.
This study looks at what influences the course of a muscle disease caused by an LMNA genetic change (a type of laminopathy). It may help researchers better understand the disease and how it affects muscle and sometimes breathing or heart function.
Hear when a new Merosin Deficient Congenital Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.